Abstract
Purpose: The Oncotype DX assay predicts the risk of 10-year distant recurrence in hormone receptor-positive, HER2-negative, node-negative early breast cancer [1]. Its use is recommended by NICE in patients with an intermediate risk of recurrence, to inform treatment decisions on adjuvant chemotherapy [2].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
